Hepatitis C

No: this is a critically important distinction from hepatitis A and B, both of which have safe and effective vaccines. Despite decades of research, no HCV vaccine currently exists, primarily because HCV has six major genotypes and an extremely high mutation rate that allows it to rapidly evolve away from immune responses. Several vaccine candidates have entered clinical trials, but none have demonstrated sufficient efficacy to reach approval. This means that unlike hepatitis A and B, prevention of hepatitis C cannot rely on vaccination: it depends entirely on avoiding blood-to-blood exposure (primarily not sharing injection equipment) and on finding and curing all existing infections, since a cured person can no longer transmit HCV.

Yes, hepatitis C is now curable for the vast majority of people. Direct-acting antiviral (DAA) medications taken orally for 8–12 weeks achieve a sustained virologic response (SVR), meaning HCV RNA is undetectable 12 weeks after the last dose, in more than 95% of people. SVR12 is considered a definitive virologic cure; the virus does not return in patients who achieve SVR and do not get re-infected. Side effects with current regimens are mild and transient. This represents one of the most striking advances in antiviral medicine, a once life-altering chronic infection with no effective treatment is now routinely cured with a short course of well-tolerated pills.

SVR (sustained virologic response) means HCV RNA is undetectable in your blood 12 weeks after you take the last dose of your treatment, this is called SVR12. SVR12 is universally accepted by hepatologists and infectious disease specialists as the definition of cure: large long-term studies have shown that more than 99% of people who achieve SVR12 remain virus-free indefinitely. Achieving SVR stops further liver damage, significantly reduces the risk of cirrhosis and liver cancer, and eliminates your ability to transmit HCV to others. However, being cured does not confer immunity to re-infection: if you have ongoing blood-to-blood exposure, you can acquire HCV again, and it will be re-treatable.

Yes. Curing HCV eliminates the virus from your body but does not create lasting immunity, your immune system does not retain protective memory against HCV the way it does after hepatitis B infection or vaccination. If you have ongoing blood-to-blood exposure, particularly sharing injection drug equipment or, for HIV-positive MSM, ongoing higher-risk sexual practices, you can be re-infected with the same or a different HCV genotype after cure. Re-infection is curable with the same DAA approach. Because your HCV antibody test will remain positive for life after any prior infection, re-infection can only be detected with an HCV RNA test, people with ongoing risk should test at least annually with RNA.

HCV spreads blood-to-blood. The most common route in the U.S. today is sharing any part of the drug-injection supply: needles, syringes, cookers, cotton, rinse water. Other documented routes include: needlestick injuries among healthcare workers (approximately 1.8% per hollow-needle stick); unregulated tattoo or piercing equipment; blood transfusions or organ transplants before 1992 (the blood supply has been screened since then and is now considered safe); perinatal transmission during delivery (approximately 5–6% risk per pregnancy); and sexual transmission, which is uncommon overall but elevated among HIV-positive MSM. HCV is not spread through casual contact: you cannot get HCV from hugging, kissing, sharing food, drinks, utensils, coughing, sneezing, or using the same toilet.

Untreated chronic HCV causes progressive liver fibrosis, replacement of functional liver tissue with scar tissue, that accumulates silently over 20–30 years. Approximately 20–30% of people with chronic, untreated HCV develop cirrhosis over this time frame, though progression rates vary significantly by cofactors such as alcohol use, HIV co-infection, and non-alcoholic fatty liver disease. Cirrhosis impairs all liver functions and can lead to decompensated liver failure (ascites, variceal bleeding, hepatic encephalopathy) requiring transplantation. People with HCV-related cirrhosis face a 1–4% annual risk of hepatocellular carcinoma (liver cancer). Curing HCV before cirrhosis prevents fibrosis progression in the vast majority of patients; curing HCV after cirrhosis develops stops further progression but does not fully reverse established scarring, and HCC surveillance must continue indefinitely.

Current first-line treatment relies on pan-genotypic direct-acting antiviral (DAA) regimens that work across all 6 HCV genotypes. The two most commonly used regimens in the U.S. are: glecaprevir/pibrentasvir (Mavyret, 3 tablets once daily for 8 weeks in treatment-naïve non-cirrhotic patients, 12 weeks if cirrhotic) and sofosbuvir/velpatasvir (Epclusa, 1 tablet daily for 12 weeks, including for cirrhotic patients). Both cure more than 95% of patients. Treatment is selected by a clinician based on genotype (if known), prior treatment history, kidney function, and drug-drug interactions. Cure is confirmed with an HCV RNA test 12 weeks after the last dose (SVR12). Treatment failures are rare but re-treatable, typically with the triple-combination regimen sofosbuvir/velpatasvir/voxilaprevir (Vosevi).

Yes, HCV and HIV share transmission routes (injection drug use and, in specific contexts, sexual transmission), so co-infection is common: an estimated 6–30% of people with HIV also have HCV, depending on the population. HIV/HCV co-infection accelerates HCV-related liver fibrosis, increases the risk of cirrhosis, and raises HCC risk at younger ages. The good news is that modern DAA regimens are equally effective in HIV-positive patients as in HIV-negative patients, achieving SVR rates of more than 95%, as long as drug-drug interactions with antiretrovirals are carefully managed. Unlike HBV, HCV does not have specific antivirals that overlap with standard ART regimens, so HCV and HIV are typically treated sequentially rather than simultaneously. HIV-positive people with HCV should be managed by providers experienced in both infections.

Yes, HCV is now recognized as a systemic disease with significant extrahepatic manifestations. The most clinically important is mixed cryoglobulinemia, in which HCV-driven immune complexes deposit in small blood vessels and cause a systemic vasculitis presenting as purpura (a characteristic rash), joint pain, peripheral neuropathy, and kidney disease, affecting an estimated 40–60% of chronic HCV patients to some degree. HCV also independently increases the risk of type 2 diabetes through insulin resistance, B-cell non-Hodgkin lymphoma through chronic B-cell stimulation, glomerulonephritis (kidney inflammation), and porphyria cutanea tarda (a blistering skin condition). Curing HCV with DAAs resolves most of these extrahepatic complications in the majority of patients, which is another reason beyond liver protection to pursue treatment.